TuHURA Biosciences, Inc.

NASDAQ:HURA

Biotechnology

Healthcare
$1.37 +6.37%

+$0.14 today

Market cap
$87.31M
Beta
0.01
P/E (TTM)
-4.6
EPS (TTM)
-$0.52
52W Low $0.41High $3.90

Volume 0.19M

Average 0.85M

HURA Operating Income

Profit from core operations after operating expenses, before interest and taxes.

TuHURA Biosciences, Inc.NASDAQ: HURA

Operating Income · Q1 FY2026 · quarter ended Mar 2026

Operating income remains negative

Q1 FY2026 operating income was -$7.53M, compared with -$7.02M a year earlier. Trailing-twelve-month operating income was -$32.31M.

Context

  • Operating income grew in size in 2 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether operating income reaches the consensus estimate from 3 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -80.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.53M+7.9% QoQ
Last fiscal yearDec 2025
-$31.8M-80.2% YoY
LTMMar 2026
-$32.31M-71.6% YoY
Operating Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.3%+100.0%+107.3 pp
1 year-80.2%+100.0%+180.2 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Income history

USD · from the income statement

Latest · FY2025
(31.8M) USD
Year-over-year change
-80.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Income vs competitors

How HURA compares with its peers on the latest reported figures

  • HURA's LTM Mar 2026 operating income of -$32.31M is the 3rd highest of the 9 companies compared; the peer median is -$58.84M.
  • Its year-over-year change of -71.6% is the lowest of 9, against a peer median of +22.6%.
HURA Competitors Peer median
Operating Income for HURA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SPROSpero Therapeutics, Inc.LTM Mar 2026$13.51M +118.2%—24.7%
AGENAgenus Inc.LTM Mar 2026$8.2M +108.1%—6.6%
HURATuHURA Biosciences, Inc.LTM Mar 2026-$32.31M -71.6%——
CGTXCognition Therapeutics, Inc.LTM Mar 2026-$42.84M +20.1%——
IRDOpus Genetics, Inc.LTM Mar 2026-$43.03M +33.1%—359.1%
SEERSeer, Inc.LTM Mar 2026-$74.65M +22.0%—496.4%
INOInovio Pharmaceuticals, Inc.LTM Mar 2026-$83.72M +21.0%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026-$87.64M +23.2%—7641.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026-$114.61M +9.5%——
Peer median (excluding HURA) -$58.84M+22.6%—359.1%

Competitors are the stored peer set for HURA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue60K60K55K00
Gross Profit(60K)(60K)(55K)00
Gross Margin—————
Research & Development15.17M9.31M2.66M13.34M20.53M
Selling, General & Admin7.45M5.43M5.73M3.87M7.58M
Operating Expenses22.62M14.74M8.4M17.65M31.8M
Depreciation & Amortization60K60K55K116.71K71.27K
EBITDA(21.97M)(14.59M)(8.27M)(17.43M)(29.36M)
EBITDA Margin—————
Operating Income(22.68M)(14.8M)(8.45M)(17.65M)(31.8M)
Operating Margin—————
Interest Income057.35K89.67K361.63K136.23K
Interest Expense629.29K018.69K4.14M625.28K
Other Income / Expenses21K147K131K(4.03M)1.74M
Income Before Tax(22.66M)(14.65M)(8.32M)(21.68M)(30.06M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(22.66M)(14.65M)(8.32M)(21.68M)(30.06M)
Net Margin—————
EPS (Basic)(903.04)(324.48)(11.29)(1.21)(0.63)
EPS (Diluted)(903.04)(324.48)(11.29)(1.21)(0.63)
Weighted Avg Shares27.83K46.29K752.91K18.66M47.93M
Weighted Avg Shares (Diluted)27.83K46.29K752.91K18.66M47.93M

TuHURA Biosciences, Inc.

NASDAQ:HURA

Intrinsic Alpha fair value

Locked

Current Price

$1.37

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.